Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
|Consolidated Key Figures (DKK'000)||2014||2015||2016||2017|
|Basic net result per share (DKK)||5.35||13.05||19.83||18.14|
|Diluted net result per share (DKK)||5.26||12.56||19.22||17.77|
|Year-end share market price (DKK)||360.30||917.50||1,173.00||1,029.00|
|Price / book value||10.09||15.67||14.67||10.04|
|Shareholders' equity per share (DKK)||35.69||58.57||79.98||102.51|
|Number of employees (FTE) at year-end||173||186||205||257|